Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses
SARS-CoV-2 mRNA booster vaccines provide protection from severe disease, eliciting strong immunity that is further boosted by previous infection. However, it is unclear whether these immune responses are affected by the interval between infection and vaccination. Over a 2-month period, we evaluated...
Gespeichert in:
| Veröffentlicht in: | Cell 2022-11, Vol.185 (23), p.4333-4346.e14 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4346.e14 |
|---|---|
| container_issue | 23 |
| container_start_page | 4333 |
| container_title | Cell |
| container_volume | 185 |
| creator | Buckner, Clarisa M. Kardava, Lela El Merhebi, Omar Narpala, Sandeep R. Serebryannyy, Leonid Lin, Bob C. Wang, Wei Zhang, Xiaozhen Lopes de Assis, Felipe Kelly, Sophie E.M. Teng, I-Ting McCormack, Genevieve E. Praiss, Lauren H. Seamon, Catherine A. Rai, M. Ali Kalish, Heather Kwong, Peter D. Proschan, Michael A. McDermott, Adrian B. Fauci, Anthony S. Chun, Tae-Wook Moir, Susan |
| description | SARS-CoV-2 mRNA booster vaccines provide protection from severe disease, eliciting strong immunity that is further boosted by previous infection. However, it is unclear whether these immune responses are affected by the interval between infection and vaccination. Over a 2-month period, we evaluated antibody and B cell responses to a third-dose mRNA vaccine in 66 individuals with different infection histories. Uninfected and post-boost but not previously infected individuals mounted robust ancestral and variant spike-binding and neutralizing antibodies and memory B cells. Spike-specific B cell responses from recent infection ( |
| doi_str_mv | 10.1016/j.cell.2022.09.032 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9513331</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S009286742201251X</els_id><sourcerecordid>2726408098</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-27f15109974cf675dcb2a1fee41f96688ac3fc35810adca894d646eed9886ff3</originalsourceid><addsrcrecordid>eNp9UcFu1DAQtRCIbhd-gAPykUuC7cSJLSGkdkWhUiUkWnG1HGdcvErsrZ0s2itfjrNbKrhwGs34ved58xB6Q0lJCW3eb0sDw1AywlhJZEkq9gytKJFtUdOWPUcrQiQrRNPWZ-g8pS0hRHDOX6KzqmG8rWi1Qr-u_QRxrwfcwfQTwONddCHi24tvt8UmfC8Ydt6CmVzwWPsedyGkzMB7bYzz-jh3406bKeFR33s3zT0ckQ-zHtx0wMHmdnJd6A_H-SVe1sYR0i74BOkVemH1kOD1Y12ju6tPd5svxc3Xz9ebi5vC1JxPBWst5dmdbGtjm5b3pmOaWoCaWtk0QmhTWVNxQYnujRay7pu6AeilEI211Rp9PMnu5m6E3oCfoh5UtjvqeFBBO_Xvi3c_1H3YK8lpVeVjrdG7R4EYHmZIkxpdWqxoD2FOirWsqYkgUmQoO0FNDClFsE_fUKKW7NRWLUy1ZKeIVDm7THr794JPlD9hZcCHEwDylfYOokrGgTfQu5gTUn1w_9P_DfIQrhI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2726408098</pqid></control><display><type>article</type><title>Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses</title><source>MEDLINE</source><source>Cell Press Free Archives</source><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Buckner, Clarisa M. ; Kardava, Lela ; El Merhebi, Omar ; Narpala, Sandeep R. ; Serebryannyy, Leonid ; Lin, Bob C. ; Wang, Wei ; Zhang, Xiaozhen ; Lopes de Assis, Felipe ; Kelly, Sophie E.M. ; Teng, I-Ting ; McCormack, Genevieve E. ; Praiss, Lauren H. ; Seamon, Catherine A. ; Rai, M. Ali ; Kalish, Heather ; Kwong, Peter D. ; Proschan, Michael A. ; McDermott, Adrian B. ; Fauci, Anthony S. ; Chun, Tae-Wook ; Moir, Susan</creator><creatorcontrib>Buckner, Clarisa M. ; Kardava, Lela ; El Merhebi, Omar ; Narpala, Sandeep R. ; Serebryannyy, Leonid ; Lin, Bob C. ; Wang, Wei ; Zhang, Xiaozhen ; Lopes de Assis, Felipe ; Kelly, Sophie E.M. ; Teng, I-Ting ; McCormack, Genevieve E. ; Praiss, Lauren H. ; Seamon, Catherine A. ; Rai, M. Ali ; Kalish, Heather ; Kwong, Peter D. ; Proschan, Michael A. ; McDermott, Adrian B. ; Fauci, Anthony S. ; Chun, Tae-Wook ; Moir, Susan</creatorcontrib><description>SARS-CoV-2 mRNA booster vaccines provide protection from severe disease, eliciting strong immunity that is further boosted by previous infection. However, it is unclear whether these immune responses are affected by the interval between infection and vaccination. Over a 2-month period, we evaluated antibody and B cell responses to a third-dose mRNA vaccine in 66 individuals with different infection histories. Uninfected and post-boost but not previously infected individuals mounted robust ancestral and variant spike-binding and neutralizing antibodies and memory B cells. Spike-specific B cell responses from recent infection (<180 days) were elevated at pre-boost but comparatively less so at 60 days post-boost compared with uninfected individuals, and these differences were linked to baseline frequencies of CD27lo B cells. Day 60 to baseline ratio of BCR signaling measured by phosphorylation of Syk was inversely correlated to days between infection and vaccination. Thus, B cell responses to booster vaccines are impeded by recent infection.
[Display omitted]
•Pre-boost SARS-CoV-2 antibodies and B cells are elevated by prior infection•Post-boost SARS-CoV-2 antibodies and B cells are muted by prior infection•Interval from infection to vaccination inversely correlates with booster response•Pre-boost RBD-specific CD21+CD27lo B cells are associated with booster response
For COVID-19 mRNA vaccines, immunization with a booster dose elicits robust antibody and B cell responses that are further increased if a breakthrough infection occurs after vaccination. In contrast, when infection occurs prior to booster vaccination, antibody and B cell responses are muted closer to the infection time and achieve better levels as the time interval between infection and vaccination increases.</description><identifier>ISSN: 0092-8674</identifier><identifier>EISSN: 1097-4172</identifier><identifier>DOI: 10.1016/j.cell.2022.09.032</identifier><identifier>PMID: 36257313</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>antibodies ; Antibodies, Neutralizing ; Antibodies, Viral ; B-Lymphocytes - immunology ; booster vaccination ; COVID-19 - prevention & control ; COVID-19 Vaccines ; Humans ; hybrid immunity ; infection ; memory B cells ; mRNA Vaccines ; SARS-CoV-2 ; Vaccination ; variants ; Viral Vaccines</subject><ispartof>Cell, 2022-11, Vol.185 (23), p.4333-4346.e14</ispartof><rights>2022</rights><rights>Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-27f15109974cf675dcb2a1fee41f96688ac3fc35810adca894d646eed9886ff3</citedby><cites>FETCH-LOGICAL-c455t-27f15109974cf675dcb2a1fee41f96688ac3fc35810adca894d646eed9886ff3</cites><orcidid>0000-0002-0163-6911</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cell.2022.09.032$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,315,782,786,887,3552,27931,27932,46002</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36257313$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Buckner, Clarisa M.</creatorcontrib><creatorcontrib>Kardava, Lela</creatorcontrib><creatorcontrib>El Merhebi, Omar</creatorcontrib><creatorcontrib>Narpala, Sandeep R.</creatorcontrib><creatorcontrib>Serebryannyy, Leonid</creatorcontrib><creatorcontrib>Lin, Bob C.</creatorcontrib><creatorcontrib>Wang, Wei</creatorcontrib><creatorcontrib>Zhang, Xiaozhen</creatorcontrib><creatorcontrib>Lopes de Assis, Felipe</creatorcontrib><creatorcontrib>Kelly, Sophie E.M.</creatorcontrib><creatorcontrib>Teng, I-Ting</creatorcontrib><creatorcontrib>McCormack, Genevieve E.</creatorcontrib><creatorcontrib>Praiss, Lauren H.</creatorcontrib><creatorcontrib>Seamon, Catherine A.</creatorcontrib><creatorcontrib>Rai, M. Ali</creatorcontrib><creatorcontrib>Kalish, Heather</creatorcontrib><creatorcontrib>Kwong, Peter D.</creatorcontrib><creatorcontrib>Proschan, Michael A.</creatorcontrib><creatorcontrib>McDermott, Adrian B.</creatorcontrib><creatorcontrib>Fauci, Anthony S.</creatorcontrib><creatorcontrib>Chun, Tae-Wook</creatorcontrib><creatorcontrib>Moir, Susan</creatorcontrib><title>Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses</title><title>Cell</title><addtitle>Cell</addtitle><description>SARS-CoV-2 mRNA booster vaccines provide protection from severe disease, eliciting strong immunity that is further boosted by previous infection. However, it is unclear whether these immune responses are affected by the interval between infection and vaccination. Over a 2-month period, we evaluated antibody and B cell responses to a third-dose mRNA vaccine in 66 individuals with different infection histories. Uninfected and post-boost but not previously infected individuals mounted robust ancestral and variant spike-binding and neutralizing antibodies and memory B cells. Spike-specific B cell responses from recent infection (<180 days) were elevated at pre-boost but comparatively less so at 60 days post-boost compared with uninfected individuals, and these differences were linked to baseline frequencies of CD27lo B cells. Day 60 to baseline ratio of BCR signaling measured by phosphorylation of Syk was inversely correlated to days between infection and vaccination. Thus, B cell responses to booster vaccines are impeded by recent infection.
[Display omitted]
•Pre-boost SARS-CoV-2 antibodies and B cells are elevated by prior infection•Post-boost SARS-CoV-2 antibodies and B cells are muted by prior infection•Interval from infection to vaccination inversely correlates with booster response•Pre-boost RBD-specific CD21+CD27lo B cells are associated with booster response
For COVID-19 mRNA vaccines, immunization with a booster dose elicits robust antibody and B cell responses that are further increased if a breakthrough infection occurs after vaccination. In contrast, when infection occurs prior to booster vaccination, antibody and B cell responses are muted closer to the infection time and achieve better levels as the time interval between infection and vaccination increases.</description><subject>antibodies</subject><subject>Antibodies, Neutralizing</subject><subject>Antibodies, Viral</subject><subject>B-Lymphocytes - immunology</subject><subject>booster vaccination</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>Humans</subject><subject>hybrid immunity</subject><subject>infection</subject><subject>memory B cells</subject><subject>mRNA Vaccines</subject><subject>SARS-CoV-2</subject><subject>Vaccination</subject><subject>variants</subject><subject>Viral Vaccines</subject><issn>0092-8674</issn><issn>1097-4172</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UcFu1DAQtRCIbhd-gAPykUuC7cSJLSGkdkWhUiUkWnG1HGdcvErsrZ0s2itfjrNbKrhwGs34ved58xB6Q0lJCW3eb0sDw1AywlhJZEkq9gytKJFtUdOWPUcrQiQrRNPWZ-g8pS0hRHDOX6KzqmG8rWi1Qr-u_QRxrwfcwfQTwONddCHi24tvt8UmfC8Ydt6CmVzwWPsedyGkzMB7bYzz-jh3406bKeFR33s3zT0ckQ-zHtx0wMHmdnJd6A_H-SVe1sYR0i74BOkVemH1kOD1Y12ju6tPd5svxc3Xz9ebi5vC1JxPBWst5dmdbGtjm5b3pmOaWoCaWtk0QmhTWVNxQYnujRay7pu6AeilEI211Rp9PMnu5m6E3oCfoh5UtjvqeFBBO_Xvi3c_1H3YK8lpVeVjrdG7R4EYHmZIkxpdWqxoD2FOirWsqYkgUmQoO0FNDClFsE_fUKKW7NRWLUy1ZKeIVDm7THr794JPlD9hZcCHEwDylfYOokrGgTfQu5gTUn1w_9P_DfIQrhI</recordid><startdate>20221110</startdate><enddate>20221110</enddate><creator>Buckner, Clarisa M.</creator><creator>Kardava, Lela</creator><creator>El Merhebi, Omar</creator><creator>Narpala, Sandeep R.</creator><creator>Serebryannyy, Leonid</creator><creator>Lin, Bob C.</creator><creator>Wang, Wei</creator><creator>Zhang, Xiaozhen</creator><creator>Lopes de Assis, Felipe</creator><creator>Kelly, Sophie E.M.</creator><creator>Teng, I-Ting</creator><creator>McCormack, Genevieve E.</creator><creator>Praiss, Lauren H.</creator><creator>Seamon, Catherine A.</creator><creator>Rai, M. Ali</creator><creator>Kalish, Heather</creator><creator>Kwong, Peter D.</creator><creator>Proschan, Michael A.</creator><creator>McDermott, Adrian B.</creator><creator>Fauci, Anthony S.</creator><creator>Chun, Tae-Wook</creator><creator>Moir, Susan</creator><general>Elsevier Inc</general><general>Cell Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0163-6911</orcidid></search><sort><creationdate>20221110</creationdate><title>Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses</title><author>Buckner, Clarisa M. ; Kardava, Lela ; El Merhebi, Omar ; Narpala, Sandeep R. ; Serebryannyy, Leonid ; Lin, Bob C. ; Wang, Wei ; Zhang, Xiaozhen ; Lopes de Assis, Felipe ; Kelly, Sophie E.M. ; Teng, I-Ting ; McCormack, Genevieve E. ; Praiss, Lauren H. ; Seamon, Catherine A. ; Rai, M. Ali ; Kalish, Heather ; Kwong, Peter D. ; Proschan, Michael A. ; McDermott, Adrian B. ; Fauci, Anthony S. ; Chun, Tae-Wook ; Moir, Susan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-27f15109974cf675dcb2a1fee41f96688ac3fc35810adca894d646eed9886ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>antibodies</topic><topic>Antibodies, Neutralizing</topic><topic>Antibodies, Viral</topic><topic>B-Lymphocytes - immunology</topic><topic>booster vaccination</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>Humans</topic><topic>hybrid immunity</topic><topic>infection</topic><topic>memory B cells</topic><topic>mRNA Vaccines</topic><topic>SARS-CoV-2</topic><topic>Vaccination</topic><topic>variants</topic><topic>Viral Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buckner, Clarisa M.</creatorcontrib><creatorcontrib>Kardava, Lela</creatorcontrib><creatorcontrib>El Merhebi, Omar</creatorcontrib><creatorcontrib>Narpala, Sandeep R.</creatorcontrib><creatorcontrib>Serebryannyy, Leonid</creatorcontrib><creatorcontrib>Lin, Bob C.</creatorcontrib><creatorcontrib>Wang, Wei</creatorcontrib><creatorcontrib>Zhang, Xiaozhen</creatorcontrib><creatorcontrib>Lopes de Assis, Felipe</creatorcontrib><creatorcontrib>Kelly, Sophie E.M.</creatorcontrib><creatorcontrib>Teng, I-Ting</creatorcontrib><creatorcontrib>McCormack, Genevieve E.</creatorcontrib><creatorcontrib>Praiss, Lauren H.</creatorcontrib><creatorcontrib>Seamon, Catherine A.</creatorcontrib><creatorcontrib>Rai, M. Ali</creatorcontrib><creatorcontrib>Kalish, Heather</creatorcontrib><creatorcontrib>Kwong, Peter D.</creatorcontrib><creatorcontrib>Proschan, Michael A.</creatorcontrib><creatorcontrib>McDermott, Adrian B.</creatorcontrib><creatorcontrib>Fauci, Anthony S.</creatorcontrib><creatorcontrib>Chun, Tae-Wook</creatorcontrib><creatorcontrib>Moir, Susan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cell</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buckner, Clarisa M.</au><au>Kardava, Lela</au><au>El Merhebi, Omar</au><au>Narpala, Sandeep R.</au><au>Serebryannyy, Leonid</au><au>Lin, Bob C.</au><au>Wang, Wei</au><au>Zhang, Xiaozhen</au><au>Lopes de Assis, Felipe</au><au>Kelly, Sophie E.M.</au><au>Teng, I-Ting</au><au>McCormack, Genevieve E.</au><au>Praiss, Lauren H.</au><au>Seamon, Catherine A.</au><au>Rai, M. Ali</au><au>Kalish, Heather</au><au>Kwong, Peter D.</au><au>Proschan, Michael A.</au><au>McDermott, Adrian B.</au><au>Fauci, Anthony S.</au><au>Chun, Tae-Wook</au><au>Moir, Susan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses</atitle><jtitle>Cell</jtitle><addtitle>Cell</addtitle><date>2022-11-10</date><risdate>2022</risdate><volume>185</volume><issue>23</issue><spage>4333</spage><epage>4346.e14</epage><pages>4333-4346.e14</pages><issn>0092-8674</issn><eissn>1097-4172</eissn><abstract>SARS-CoV-2 mRNA booster vaccines provide protection from severe disease, eliciting strong immunity that is further boosted by previous infection. However, it is unclear whether these immune responses are affected by the interval between infection and vaccination. Over a 2-month period, we evaluated antibody and B cell responses to a third-dose mRNA vaccine in 66 individuals with different infection histories. Uninfected and post-boost but not previously infected individuals mounted robust ancestral and variant spike-binding and neutralizing antibodies and memory B cells. Spike-specific B cell responses from recent infection (<180 days) were elevated at pre-boost but comparatively less so at 60 days post-boost compared with uninfected individuals, and these differences were linked to baseline frequencies of CD27lo B cells. Day 60 to baseline ratio of BCR signaling measured by phosphorylation of Syk was inversely correlated to days between infection and vaccination. Thus, B cell responses to booster vaccines are impeded by recent infection.
[Display omitted]
•Pre-boost SARS-CoV-2 antibodies and B cells are elevated by prior infection•Post-boost SARS-CoV-2 antibodies and B cells are muted by prior infection•Interval from infection to vaccination inversely correlates with booster response•Pre-boost RBD-specific CD21+CD27lo B cells are associated with booster response
For COVID-19 mRNA vaccines, immunization with a booster dose elicits robust antibody and B cell responses that are further increased if a breakthrough infection occurs after vaccination. In contrast, when infection occurs prior to booster vaccination, antibody and B cell responses are muted closer to the infection time and achieve better levels as the time interval between infection and vaccination increases.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36257313</pmid><doi>10.1016/j.cell.2022.09.032</doi><orcidid>https://orcid.org/0000-0002-0163-6911</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0092-8674 |
| ispartof | Cell, 2022-11, Vol.185 (23), p.4333-4346.e14 |
| issn | 0092-8674 1097-4172 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9513331 |
| source | MEDLINE; Cell Press Free Archives; Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals |
| subjects | antibodies Antibodies, Neutralizing Antibodies, Viral B-Lymphocytes - immunology booster vaccination COVID-19 - prevention & control COVID-19 Vaccines Humans hybrid immunity infection memory B cells mRNA Vaccines SARS-CoV-2 Vaccination variants Viral Vaccines |
| title | Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T07%3A58%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interval%20between%20prior%20SARS-CoV-2%20infection%20and%20booster%20vaccination%20impacts%20magnitude%20and%20quality%20of%20antibody%20and%20B%20cell%20responses&rft.jtitle=Cell&rft.au=Buckner,%20Clarisa%20M.&rft.date=2022-11-10&rft.volume=185&rft.issue=23&rft.spage=4333&rft.epage=4346.e14&rft.pages=4333-4346.e14&rft.issn=0092-8674&rft.eissn=1097-4172&rft_id=info:doi/10.1016/j.cell.2022.09.032&rft_dat=%3Cproquest_pubme%3E2726408098%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2726408098&rft_id=info:pmid/36257313&rft_els_id=S009286742201251X&rfr_iscdi=true |